Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report

Severe coronavirus disease 2019 can be associated with progressive respiratory failure. In addition to respiratory support and other supportive care, use of corticosteroids has shown to improve outcome. Despite the use of steroids, a significant proportion of patients progressively worsen. Adjunct i...

Descripción completa

Detalles Bibliográficos
Autores principales: Shrestha, Gentle Sunder, Bista, Bidesh, Dhungana, Ashesh, Poudel, Nimesh, Bhattarai, Shraddha, Shrestha, Manjit, Bhandari, Sandip, Vaidya, Binit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of the Nepal Medical Association 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369566/
https://www.ncbi.nlm.nih.gov/pubmed/34508399
http://dx.doi.org/10.31729/jnma.6680
Descripción
Sumario:Severe coronavirus disease 2019 can be associated with progressive respiratory failure. In addition to respiratory support and other supportive care, use of corticosteroids has shown to improve outcome. Despite the use of steroids, a significant proportion of patients progressively worsen. Adjunct immunomodulators have been studied in addition to steroids in these patients. Here we present a successful use of tofacitinib, a Janus Kinase inhibitor, in conjunction with dexamethasone for a patient with rapid worsening of respiratory status and with high level of serum inflammatory biomarkers.

Ejemplares similares